Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 9, 2000, Pages 3132-3140

  Colao, Annamaria ^a   Marzullo, Paolo ^a   Ferone, Diego ^a   Spinelli, Letizia ^a   Cuocolo, Alberto ^a,b   Bonaduce, Domenico ^a   Salvatore, Marco ^a   Boerlin, Viktor ^c   Lancranjan, Ioana ^c   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS NEUROMED   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART SCINTISCANNING; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; PRIORITY JOURNAL;

EID: 0033710082     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.9.3132     Document Type: Article

References (45)

1. Acromegaly
2. Mortality in acromegaly
3. Epidemiology and long-term survival in acromegaly
4. Determinants of clinical outcome and survival in acromegaly
5. Mortality and cancer incidence in acromegaly: A retrospective cohort study
6. Cardiac hypertrophy and function in asymptomatic acromegaly
7. Evidence for biventricular involvement in acromegaly: A Doppler echocardiographic study
8. Impaired left ventricular diastolic function in acromegaly: An echocardiographic study
9. Subclinical cardiac dysfunction in acromegaly: Evidence for a specific disease of heart muscle
10. Acromegalic cardiopathy: A left ventricular scintigraphic study
11. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension
12. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study
13. Acromegaly
14. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics
15. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
16. Growth hormone and the heart
17. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study
18. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide
19. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
20. Effects of octreotide on left ventricular mass in acromegaly
21. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients
22. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog)
23. Cardiovascular effects of the somatostatin analog octreotide in acromegaly
24. Cardiovascular aspects in acromegaly: Effects of treatment
25. Growth-hormone and prolactin excess
26. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly
27. Sandostatin-LAR: Pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients
28. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly
29. Depot long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly
30. Sandostatin LAR in acromegalic patients: Long-term treatment
31. Prediction of efficacy of octreotide therapy in patients with acromegaly
32. The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements
33. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion
34. Impaired left ventricular diastolic filling in patients with coronary artery disease: Assessment with radionuclide angiography
35. Left ventricular peak ejection rate, filling rate and ejection fraction: Frame requirements at rest and exercise
36. An audit of outcome of treatment in acromegaly
37. Criteria for cure of acromegaly: A consensus statement
38. Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections
39. Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy
40. Octreotide treatment increases exercise capacity in patients with acromegaly
41. Cardiopulmonary performance during exercise in acromegaly and the effects of acute suppression of growth hormone hypersecretion with octreotide
42. Localisation and quantitation of autonomic innervation in the porcine heart I: Conduction system
43. Effect of octreotide pretreatment on surgical outcome in acromegaly
44. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly